Y0000472

Cabergoline

European Pharmacopoeia (EP) Reference Standard

Manufacturer: Sigma Aldrich

CAS Number: 81409-90-7

Synonym(S): 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336

Select a Size

Pack Size SKU Availability Price
170 MG Y0000472-170-MG In Stock ₹ 14,267.35

Y0000472 - 170 MG

₹ 14,267.35

In Stock

Quantity

1

Base Price: ₹ 14,267.35

GST (18%): ₹ 2,568.123

Total Price: ₹ 16,835.473

grade

pharmaceutical primary standard

API family

cabergoline

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1

InChI

1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

InChI key

KORNTPPJEAJQIU-KJXAQDMKSA-N

Gene Information

human ... DRD2(1813)

Other Options

Related Products

Img

Sigma Aldrich

Y0000501

European Pharmacopoeia (EP) Referen...

Img

Sigma Aldrich

Y0001027

European Pharmacopoeia (EP) Referen...

Img

Sigma Aldrich

Y0000352

European Pharmacopoeia (EP) Referen...

Img

Sigma Aldrich

Y0000469

European Pharmacopoeia (EP) Referen...

Img

Sigma Aldrich

Y0000515

European Pharmacopoeia (EP) Referen...

Description

  • General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
  • Application: Cabergoline EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
  • Biochem/physiol Actions: Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
  • Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
  • Other Notes: Sales restrictions may apply.

SAFETY INFORMATION

Pictograms

GHS07

Signal Word

Warning

Hazard Statements

H302,H362

Precautionary Statements

P202 - P260 - P263 - P264 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Lact.

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable